



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julius Remenar et al.

Application No.: 10/601,092

Filed: June 20, 2003

For: PHARMACEUTICAL

COMPOSITIONS WITH IMPROVED

DISSOLUTION

Atty. Docket No.: TPIP017

Examiner: Unassigned

Group: Unassigned

Date: August 21, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, PO Box 1450, Alexandria, VA 22313 on August 21, 2003.

Signed:

Jacquie M. Vo

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.56 AND 1.97(c)

Assistant Commissioner for Patents Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 1449, copies of which are attached, may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.


This Information Disclosure Statement is being filed within three (3) months of the filing date of the above-referenced application. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2626 (Order No. TPIP017).

Respectfully submitted,

Paul Burgess

Reg. No. 53,852

Transform Pharmaceuticals, Inc. 29 Hartwell Avenue Lexington, MA 02421



449 (Modified)

Atty Docket No. Application No.: TPIP017

Inventor

10/601,092 Julius Remenar et al.

Group

Filing Date

Unassigned June 20, 2003

(Use Several Sheets if Necessary)

Information Disclosure

Statement By Applicant

U.S. Patent Documents

C.B. I atent Documents							
Examiner		1				Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
	A	6,294,192	9/25/2001	Patel et al.	t		
	В						
	C						
	D					<u> </u>	
	E						

Foreign Patent or Published Foreign Patent Application

Examiner	T	Document	Publication	Country or		Sub-	Trans	lation
Initial	No.	No.	Date	Patent Office	Class	class	Yes	No
	F	00/32189	6/8/2000	WIPO				
	G	01/41760	6/14/2001	WIPO				
	Н	01/42221	6/14/2001	WIPO		,		
	I	01/42222	6/14/2001	WIPO				
	J	01/78724	10/25/2001	WIPO				
	K	01/91750	12/6/2001	WIPO				
	L	02/00627	1/3/2002	WIPO				

Other Documents

Examiner					
Initial	No.	Author, Title, Date, Place (e.g. Journal) of Publication			
	M	Fitzgerald, Garret A., "The Coxibs, Selective Inhibitors of Cyclooxygenase-2", New England Journal of Medicine, Vol. 345, No. 6, August 9, 2001.			
}	N				
L					
Examiner	٠.	Date Considered			

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.